Zhitong Financial APP learned that Olympic Star Life Technology (06118) opened nearly 5% higher in early trading and rose 4.85% as of 09:20, with an offer of HK $16.00 and a turnover of 48000.
A few days ago, the novel coronavirus mutant Omicron (Omicron), which was first found in South Africa and other countries, has spread in more countries and regions outside Africa, and its infectivity and pathogenicity may increase, and may lead to immune escape and a decline in the protective effectiveness of the existing COVID-19 vaccine, which makes the limitations of the early vaccine and the urgent need for a better vaccine more obvious.
Recently, the research team led by Liu Liang, director of the State key Laboratory of traditional Chinese Medicine quality Research of Macao University of Science and Technology, is the first candidate COVID-19 vaccine in the world to use adeno-associated virus serotype 5 as vector and RBD on SARS-CoV-2 spike protein (S protein) and its extended domain (RBD-plus) as immune antigen-recombinant novel coronavirus vaccine (AAV5 vector), which has entered clinical trials. The recombinant novel coronavirus vaccine is a candidate COVID-19 vaccine designed with AAV5 as the carrier and RBD-plus as the immune antigen. in the preclinical study, it shows the significant advantages of strong immune efficacy, long-lasting immune efficacy, good safety, high accessibility, intramuscular injection or nasal drip and only one vaccination, and there is no need for stringent cold chain transportation. At the same time, it also has the potential to effectively prevent COVID-19 caused by unknown mutants at present or in the future.
It is reported that Aoxing Life Technology (06118) and Guangdong Qingheng Biopharmaceutical Co., Ltd. have signed an agreement for Guangdong Qingheng Biopharmaceutical Co., Ltd. to invest 640 million yuan for the vaccine to be settled in Fengshun, Guangdong Province, to build a Fengshun vaccine production base; Aoxing Life Technology provides it with 420 million yuan of vaccine production equipment, pharmaceutical facilities and related services.
Vaccine production needs to be carried out in a high-level biosafety environment, and strict biosafety measures are needed from the building as a whole, negative pressure workshop, pharmaceutical equipment to all production links.
According to the characteristics of the new COVID-19 vaccine, Aoxing Life Science and Technology provides personalized and comprehensive solutions for Fengshun production base in project certification, plant construction design, GEP project management, purified water, pure steam preparation and distribution system, vaccine workshop liquid distribution and purification and CIP system, vaccine workshop overall biological pollution removal system (VHP), automatic control, intelligence and other plant construction and production process. After the project is put into production, it is estimated that 240 million pieces of adeno-associated virus vector COVID-19 vaccine will be produced annually.